Omnitrope Drug Interactions: What to Avoid and What to Tell Your Doctor

Omnitrope (somatropin) interacts with several important categories of medications. Some interactions reduce Omnitrope's effectiveness; others require dose adjustments for the interacting drug; and one — with the diagnostic agent macimorelin — requires Omnitrope to be stopped completely before the test. Telling your doctor and pharmacist about every medication, supplement, and vitamin you take before starting Omnitrope is essential.

The Most Important Omnitrope Drug Interactions

1. Macimorelin (Macrilen) — Avoid Combination

Macimorelin (brand name Macrilen) is a diagnostic agent used to test for adult GHD. It works by stimulating growth hormone release. If you take Omnitrope at the same time as a macimorelin test, Omnitrope will blunt the body's GH response to macimorelin — leading to a false-negative result (the test will incorrectly suggest you don't have GHD even if you do).

Action required: Discontinue Omnitrope at least 1 week (7 days) before a macimorelin diagnostic test. Talk to your endocrinologist about timing.

2. Glucocorticoids (Corticosteroids) — Major Interaction

This is the most clinically relevant drug-drug interaction for most Omnitrope patients. Glucocorticoids include:

• Prednisone, prednisolone, methylprednisolone (Medrol)
• Hydrocortisone (replacement therapy for adrenal insufficiency)
• Dexamethasone, budesonide, and other synthetic steroids

Pharmacologic doses of glucocorticoids oppose the growth-promoting effects of Omnitrope, reducing its effectiveness. In children on long-term steroid therapy (for asthma, inflammatory conditions, or adrenal insufficiency), the GH response to Omnitrope may be blunted significantly.

Separately, Omnitrope can inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that converts inactive cortisone to active cortisol in tissues. This means patients on hydrocortisone or prednisone as replacement therapy for adrenal insufficiency may need higher replacement doses to maintain adequate cortisol activity. Monitor patients starting Omnitrope who are on glucocorticoid replacement.

3. Insulin and Antidiabetic Medications — Monitor Closely

Omnitrope reduces insulin sensitivity. For patients with diabetes or prediabetes, this can worsen blood glucose control. Dose adjustments for insulin, metformin, sulfonylureas (glipizide, glimepiride), GLP-1 agonists (semaglutide, liraglutide), and other antidiabetic medications may be necessary after starting Omnitrope.

Monitor blood glucose carefully when initiating or adjusting Omnitrope, and inform your endocrinologist if you notice symptoms of high blood sugar: increased thirst, frequent urination, fatigue, or blurred vision.

4. Thyroid Hormone (Levothyroxine) — Unmasks Hypothyroidism

Omnitrope can reduce thyroid hormone levels, sometimes unmasking subclinical hypothyroidism. Patients who are already on levothyroxine (Synthroid, Levoxyl) may find their thyroid hormone requirements change after starting Omnitrope. Patients not yet on thyroid medication may develop new hypothyroidism that requires treatment.

Regular thyroid function monitoring (TSH, free T4) is recommended during Omnitrope treatment. Signs of hypothyroidism: fatigue, weight gain, cold intolerance, constipation, dry skin.

5. CYP3A4 Substrates — Increased Drug Metabolism

Growth hormone has been shown to increase the activity of cytochrome P450 (CYP450) enzymes in the liver, particularly CYP3A4. This can accelerate the metabolism (breakdown) of medications that are processed by this enzyme, potentially reducing their blood levels and effectiveness. Medications affected include:

• Sex hormones: Estrogens (including oral contraceptives and hormone replacement therapy) and testosterone may have reduced systemic exposure. Oral estrogen in women with GHD may also reduce the IGF-1 response to Omnitrope — women on oral estrogen may need higher Omnitrope doses.
• Anticonvulsants: Drugs like carbamazepine, phenytoin, and others may have altered levels when Omnitrope is started or stopped.
• Cyclosporine: Blood levels of cyclosporine (an immunosuppressant used after organ transplants) may be affected. Close monitoring is warranted.

6. Oral Estrogen — Reduces Omnitrope Effectiveness in Women

Women taking oral estrogen therapy (hormone replacement therapy or oral contraceptives) may have a blunted IGF-1 response to Omnitrope. This is because oral estrogen reduces hepatic IGF-1 production. Women in this situation may need higher Omnitrope doses than men or women on transdermal (patch/gel) estrogen to achieve the same IGF-1 target. Discuss with your endocrinologist if you take oral estrogen.

What to Tell Your Doctor Before Starting Omnitrope

Make sure your endocrinologist and pharmacist know about all of the following:

• All prescription medications (including any steroids, thyroid hormone, diabetes medications, or immunosuppressants)
• Over-the-counter medications (including NSAIDs, antihistamines, and sleep aids)
• Vitamins and dietary supplements (especially high-dose vitamins, herbal supplements, and hormone supplements)
• History of cancer, radiation treatment, or organ transplant
• Diabetes or prediabetes (or family history of diabetes)
• Thyroid conditions

For a complete guide to Omnitrope side effects and what to watch for during treatment, see: Omnitrope side effects: what to expect and when to call your doctor.